Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (February 2020)
31 slides from Osteopore's investor presentation, Feb 7, 2020
Slide 1: Investor Presentation – February 2020
For personal use only Breakthrough 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore Limited (ASX: OSX) Investor Presentation – February 2020
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not tr
Slide 3: Company Overview
Osteopore Limited (ASX: OSX) For personal use only – Company Overview Osteopore Limited (ASX: OSX) is an Australian / Singapore-based medical technology company that specialises in the production of 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore’s prod
Slide 4: Corporate and Capital Structure
For personal use only Osteopore Limited (ASX: OSX) Corporate and Shares on Issue 101.2m Capital Structure Capital Structure Total Options on Issue 9.7m o No debt Market Cap @ $0.62c* $62.7m o 51.4m shares under escrow for 12-24 months EV @ $0.62c* $59.3m o Options could provide an additional $2.4m i
Slide 5: Investment Highlights
For personal use only Osteopore Limited (ASX: OSX) 5 Investment Highlights Revenue Generating Proprietary Technology Scalable Business Model Over AUD$1.1m in revenues for the twelve Osteopore has licensed a range of patented High margin products with low capital month period to 31 December 2019, wit
Slide 6: Milestones Since IPO
For personal use only Osteopore Limited (ASX: OSX) 6 Milestones Since IPO OSTEOPORE – REVENUE GROWTH ACHIEVEMENTS SINCE IPO QUARTER ON QUARTER ANNUAL GROWTH CY Significant quarterly revenue growth, increasing GROWTH CY 2019 2016 - 2019 21% over previous quarter to A$363,000 A$1,101,833 Highest calen
Slide 7: Founder, Management and Board of Directors
For personal use only Osteopre Limited (ASX: OSX) Partner of Ventnor Capital, Brett Sandercock Non-Executive Chairman or Founder, Management Non-Exec Chairman Director of a number of ASX listed entities and Board of Directors Current CFO of Resmed (ASX:RMD / NYSE: RMD) and Senior executive at Stuart
Slide 8: Regenerative Medicine
For personal use only Tissue engineering, 3D printed microarchitecture and regenerative medicine concepts are at the heart of the Osteopore technology. Osteopre Limited (ASX: OSX) Regenerative medicine treats injuries and diseases by Regenerative Medicine harnessing the body’s own regenerative capab
Slide 9: Customisable 3D printed bioresorbable implants
For personal use only Customisable 3D printed bioresorbable implants to enable the natural stages of bone healing across multiple applications. Highly customisable Naturally dissolves Leaves only healthy Reduces post surgery Unlikely inflammation to biomimic different over time bone tissue complicat
Slide 10: Proprietary Bioresorbable Scaffold Technology
Osteopore Solution For personal use only Proprietary Bioresorbable Scaffold Technology Osteopore’s proprietary 3D printed polymer scaffold is made up Osteopore Scaffold of biomimetic microstructures that facilitate natural tissue regeneration after insertion into the human body. Angiogenesis – Early
Slide 11: Current Approaches to Bone Regeneration
For personal use only Osteopore Solution Current Approaches to Bone Regeneration Currently, there are three main treatment Bone Graft Permanent Implants Bio-Materials strategies to augment the bone-regeneration process, including the 'gold standard' bone A surgical procedure where bone Permanent mat
Slide 12: Products & Applications
For personal use only Osteopore Solution 12 Products & Applications Bioresorbable implant that is Bioresorbable implant that is used in Provides a durable, biodegradable Patient Specific Implants (PSI) based on used for covering Burr Holes craniofacial surgery to repair various method of filling the
Slide 13: Proven to Facilitate Bone Healing – Burr Hole Example
1 Month Post-Operation CT Imagery For personal use only Patients needing surgical repair for skull fractures usually receive a “burr hole” during surgery, which is drilled into the skull to relieve pressure from haemorrhage. To repair the burr hole, common methods include harvesting bone from anothe
Slide 14: Clinical Success - Patient Specific Implants
For personal use only Osteopore Solution Clinical Success - Patient Specific Implants Bone Defect Early Mineralisation Walking Bone Remodeling 150mm bone loss due to Initial osseous ingrowth with Able to walk without Complete bone bridging tumor resection 20kg partial weight-bearing assistance from
Slide 15: Osteopore Offers Unique Therapeutic Value Proposition
Osteopore Solution For personal use only 15 Osteopore Offers Unique Therapeutic Value Proposition There are no other FDA or CE Mark cleared products that offer Microporous Osteopore’s key technology characteristics – bio-resorption and (Biomimetic Structure) biomimetic structure - which offer improv
Slide 16: Market Opportunities & Growth Strategy
For personal use only Market Opp rtunities & Growth Strategy
Slide 17: Business and Revenue Model
For personal use only Market Opportunity & Growth Strategy Business and Revenue Model Distribution Networks Given the high wholesale margins and low capital intensity of the 3-D printing-based manufacturing process, Osteopore is focused on building distribution networks for its products while retain
Slide 18: Opportunities in Multi-Billion Dollar Global Markets
For personal use only Market Opportunity & Growth Strategy Opportunities in Multi-Billion Dollar Global Markets Current Sales Current market opportunities Current sales of Osteopore products are pre- (Bone Graft substitutes, US$3.9bn by 2025) dominantly in Cranial / Maxillofacial (CMF) area, Permane
Slide 19: Revenue Growth Strategy
Market Opportunity & Growth Strategy 19 For personal use only Revenue Growth Strategy Osteopore is now looking to build value through short, medium and long term strategic goals. Revenue Expansion o Growth in revenue from existing Asian markets Phase One Increase underlaying revenue from its o Estab
Slide 20: Phase One: Revenue Expansion
20 For personal use only Revenue Growth Strategy Phase ne Revenue Expansion The Company aims enhance market penetration of the commercially Phase Two ready Osteoplug, Osteomesh and Osteostrip products Phase Three Building underlying revenue base organically from Asian markets and building distributi
Slide 21: Phase Two: New Therapeutic Segments
21 For personal use only Phase One Phase Tw Dental Orthopaedic Phase Three Osteopore has developed an enhanced Osteopore has successfully bioresorbable 3D-printed dental plug conducted first in human trials which promotes bone growth in the jaw, using the Osteopore scaffold in a reducing the likelih
Slide 22: Phase Three: Future Horizons
22 Phase One For personal use only Phase Two Revenue Growth strategy Phase Three Future Horizons Accelerating Bone Regeneration Osteopore is investigating the viability of incorporating bioactive materials into polycaprolactone polymer material, which could be used to improve patient outcomes. These
Slide 23: Building blocks in place for executing growth strategy
For personal use only Building bl cks in place for executing growth strategy
Slide 24: Scalable & Customisable Manufacturing
For personal use only Building blocks for execution Integration of Medical Imaging, Computational Mechanics & Biomaterials Technology Scalable & Customisable Step One Manufacturing The hospital undertakes a CT scan. Low cost 3D printing process to customise Step Two products and maintain IP advantag
Slide 25: Global Regulatory Approval
For personal use only Building blocks for execution Global Regulatory Approval Current regulatory clearances Potential Future clearances 25
Slide 26: Intellectual Property
For personal use only Building blocks for execution Intellectual Property Osteopore technology is supported by granted patents from leading Singaporean research institutions. Method for Bioresorbable 3-D Bioresorbable Resorbable Bioresorbable- Fabricating a Plug Implants Scaffolds for Tissue Scaffol
Slide 27: Research & Development Partners
For personal use only Building blocks for execution Research & Development Partners Osteopore has exclusive license arrangements with Nanyang Technological University (NTU), National University of Singapore (NUS) and Temasek Polytechnic. And a number of key research and development relationships wit
Slide 28: Media & Awards Exposure
For personal use only Building blocks for execution Media & Awards Exposure Unique nature of Osteopore’s products and procedures provides the Company with a high level of public exposure Business Model through media coverage and prestigious Innovation Award 2018 awards Recent coverage of Australian
Slide 29: Management Team
For personal use only Building blocks for execution 29 Management Team Geoff Pocock Goh Khoon Seng Executive Director Chief Executive Officer Formerly Managing Director of Hazer Mr Goh has a 30-year career spaning both start-ups and Group Ltd (ASX:HZR) and Non-Executive global multinational corporat
Slide 30: ASX Peers Show Potential for Value Re-rating
For personal use only Building blocks for execution 30 ASX Peers Show Potential for Value Re-rating PolyNovo (ASX: PNV) Medical devices for the treatment of burns, AU$13.6m Revenue FY19 $1.85bn Market Cap surgical wounds and Negative Pressure Wound Therapy. Mesoblast (ASX: MSB) Cellular medicines to
Slide 31: For personal use only
For personal use only Investor Presentation 2020 Geoff Pocock Executive Director M +61 412 194 373 E: geoff_pocock@osteopore.com